ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC"
Episode Synopsis
Amivantamab Approved by FDA today, March 1!
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.
More episodes of the podcast Lung Cancer Considered
Lung Cancer Considered in Hungarian
31/10/2025
LCC in Greek: WCLC 2025 Highlights
10/10/2025
LCC in Arabic: WCLC 2025 Highlights
03/10/2025
Lung Cancer Considered: Targeting EGFR NSCLC
03/10/2025
LCC in Korean: WCLC 2025 Highlights
30/09/2025
In God we trust